Back

Regulatory science meets artificial intelligence: pathways for approval of artificial intelligence-developed cardiometabolic drugs

31 August 2026 (14:45 - 15:00)
Organised by: Logo
Congress Presentation Part of: Artificial intelligence in cardiometabolic drug discovery: from molecular insight to regulatory approval Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Piotr Szymanski

National Institute of Medicine MSWiA, Warszawa (Poland)

3 More presentations in this session

Presentation thumbnail
Artificial intelligence-enabled target discovery: decoding cardiometabolic pathways from omics to mechanism
Doctor M. Kelm (Berlin, DE)
Slides Video
Presentation thumbnail
Digital trials: how artificial intelligence optimises phenotyping, recruitment, and adaptive designs in cardiometabolic therapeutics
Doctor S. Niederer (London, GB)
Slides Video
Presentation thumbnail
Artificial intelligence in cardiometabolic drug discovery: from molecular insight to regulatory approval - discussion
Video

Access the full session

Session thumbnail
Artificial intelligence in cardiometabolic drug discovery: from molecular insight to regulatory approval
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 14:45 CET
You may be interested in
thumbnail
Congress Presentation
Regulatory aspects on use of AI in Europe
31 August 2025
thumbnail
Congress Presentation
Artificial intelligence as a new approach methodology
29 August 2026
thumbnail
Congress Presentation
Artificial intelligence in cardiovascular imaging: hype or hope? - discussion
29 August 2026
thumbnail
Congress Presentation
Artificial intelligence agents in medicine: what level of autonomy can we accept?
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources